The efficacy of BILN 2061 in humans establishes proof-of-concept for an NS3 protease inhibitor and a new class of a selective anti-HCV agent that was specifically designed to inhibit an essential ...
To follow NS3-catalysed unwinding, we flow NS3 (1–90 nM) and ATP (0.05–1 mM) together in buffer U (see Methods). We then hold the RNA substrate at a constant force of between 5 and 17 pN. NS3 loads on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results